GSK’s RSV vaccine receives expanded FDA approval – STAT

The Food and Drug Administration on Friday expanded the approval for GSKs vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

Arexvy, which was the first RSV vaccine approved, now becomes the first to be available to adults under the age of 60 who are not pregnant. Prior to this FDA decision, Arexvy was licensed for use in people 60 and older. Since the initial FDA approval, the vaccine has been licensed in more than 40 countries.

Todays approval reflects the importance of broadening the benefits of RSV immunization to adults aged 50-59 who are at increased risk, GSKs chief scientific officer, Tony Wood, said in a statement. For those with underlying medical conditions, RSV can have serious consequences, so we are proud to be the first to help protect them.

STAT+ Exclusive Story

Already have an account? Log in

Already have an account? Log in

Already have an account? Log in

Get unlimited access to award-winning journalism and exclusive events.

Read more here:

GSK's RSV vaccine receives expanded FDA approval - STAT